MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple Myeloma
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in
Multiple Myeloma
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the
first patient in a Phase 1/2a clinical trial of its cancer antibodyMOR202 has
been dosed. MOR202 is a fully human HuCAL antibody directed against CD38, a
therapeutic target which is highly expressed on multiple myeloma tumor cells and
certain leukemias. The phase 1/2a, open-label, multi-centre, dose-escalation
study will evaluate the safety and preliminary efficacy of MOR202 in patients
with relapsed or refractory multiple myeloma.
"We will evaluate MOR202 both as a monotherapy and in combination with standard
therapy. I am very pleased that this program has been brought forward so
successfully by our development team over the past months and now represents
another valuable clinical asset in our portfolio. In total, this is our third
proprietary antibody program in clinical trials, following MOR103 in rheumatoid
arthritis and MOR208 in chronic lymphocytic leukemia," commented Dr. Arndt
Schottelius, Chief Development Officer of MorphoSys AG.
Patients with relapsed or refractory multiple myeloma will be treated with
different doses of the HuCAL-derived antibody MOR202. It is also planned to
evaluate the safety of MOR202 in combination with approved therapy. Pre-clinical
studies recently presented at the 2011 Annual Meeting of the American Society of
Clinical Oncology (ASCO) demonstrated enhanced cytotoxic activity of MOR202 in
combination with Velcade(®) and Revlimid(®), supporting the clinical trial
design.
In total, the clinical trial* is anticipated to enroll a maximum of 82 patients
and will be conducted in several centers in Germany and Austria. The primary
endpoints of the trial are to determine the safety and tolerability of multiple
doses of MOR202 in patients. Secondary outcome measures will evaluate
pharmacokinetics and preliminary efficacy.
More information on the trial can be found by searching for MorphoSys at
http://clinicaltrials.gov.
*Supported by the German Federal Ministry of Education and Research as part of
Munich's leading edge cluster m4 - Personalized medicine and targeted therapies
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys; arYla(TM) is a trademark of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Media Release:
http://hugin.info/130295/R/1543179/472638.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1543179]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Globex Royalty Property Receives Positive Preliminary Economic Assessment and Other NewsDatum: 01.09.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 61380
Anzahl Zeichen: 6664
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 261 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple Myeloma"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
